ArticleCancer medicine2021
A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab.
Xiaoling Shang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it